Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-05-20
2008-05-20
Mondesi, Robert B. (Department: 1652)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07375076
ABSTRACT:
The present invention is a method of reducing vascular permeability in tissue of a subject comprising inhibiting the activity of serine proteinase tissue-type plasminogen activator (tPA). This tPA activity which increases permeability of the tissue in a subject results in edema in the tissue is separate from tPA's thrombolytic activity. The present invention more specifically relates to administering an amount of a tPA inhibitor sufficient to reduce the vascular permeability increasing activity of tPA in a subject. Useful tPA inhibitors for the present method are neuroserpin, mutant neuroserpin, wild-type PAI-1, mutant PAI-1, an antibody that binds to tPA, an antibody that binds to the low-density lipoprotein (LDL) receptor or a low-density lipoprotein (LDL) receptor family antagonist.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4485045 (1984-11-01), Regen
patent: 4544545 (1985-10-01), Ryan et al.
patent: 6008020 (1999-12-01), Hastings et al.
patent: 6103498 (2000-08-01), Lawrence et al.
patent: 6191260 (2001-02-01), Hastings et al.
patent: 6489143 (2002-12-01), Lawrence et al.
patent: 32 18 121 (1983-11-01), None
patent: 0 102 324 (1983-07-01), None
patent: 0 133 988 (1984-08-01), None
patent: 0 142 641 (1984-08-01), None
patent: 0 052 322 (1985-03-01), None
patent: 0 143 949 (1985-06-01), None
patent: 0 058 481 (1986-10-01), None
patent: 0 036 676 (1990-09-01), None
Hastings et al., Neuroserpin, a Brain-associated Inhibitor of Tissue Plasminogen Activator Is Localized Primarily in Neurons, JBC, vol. 272, No. 52, Issue of Dec. 26, 1997 pp. 33062-33067.
Rudd et al., Thrombolytic therapy causes an increase in vascular permeability that is reversed by 1-deamino-8-D-vasopressin, Circulation. Dec. 1991; vol. 84, No. 6, pp. 2568-2573.
Thomas H. Bugge et al., “Loss of Fibrinogen Rescues Mice from the Pieiotropic Effects of Plasminogen Deficiency”, Cell, vol. 87, pp. 709-719, Nov. 15, 1996.
Stella E. Tsirka et al., “Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator”, Nature, vol. 377, pp. 340-344, Sep. 28, 1995.
Zhuo Qian et al., “Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation”, Nature, vol. 361, pp. 453-457, Feb. 4, 1993.
Nicholas W. Seeds et al., “Tissue Plasminogen Activator Induction in Purkinje Neurons After Cerebellar Motor Learning”, Science, vol. 270, pp. 1992-1578, Dec. 22, 1995.
“Tissue Plasminogen Activator for Acute Ischemic Stroke”, The New England Journal of Medicine, vol. 333, No. 24, pp. 1581-1587, Dec. 14, 1995.
Yanming F. Wang et al., “Tissue Plasminogen Activator (tPA) Increases Neuronal Damage After Focal Cerebral Ischemia in Wild-Type and tPA-Deficient Mice”, Nature Medicine, vol. 4, No. 2, Feb. 1998, pp. 228-231.
N. Nagai et al., “Role of Plasminogen System Components in Focal Cerebral Ischemic Infarction, A Gene Targeting and Gene Transfer Study in Mice”, Plasminogen System and Cerebral Infarction, May 11, 1999, pp. 2440-2444.
Manuel Yepes et al., “Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis”, Hemostasis, Thrombosis & Vascular Biology, Blood, Jul. 15, 2000, vol. 96, No. 2, pp. 569-576.
Paolo Cinelli et al., “Neuroserpin, a Neuroprotective Factor in Focal Ischemic Stroke”, Molecular and Cellular Neuroscience 18, pp. 443-457 (2001).
Pamela M. Carroll et al., “The mouse tissue plasminogen activator gene 5′ flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS”, Development 120, pp. 3173-3183 (1994).
Zhenggang Zhang et al., “Adjuvant Treatment With Neuroserpin Increases the Therapeutic Window for Tissue-Type Plasminogen Activator Administration in a Rat Model of Embolic Stroke”, Circulation, Aug. 6, 2002, pp. 740-745.
Toshiaki Aoki Ph.D. et al., “Blood-Brain Barrier Disruption and Matrix Metalloproteinase-9 Expression During Reperfusion Injury Mechanical Versus Embolic Focal Ischemia in Spontaneously Hypertensive Rats”, Stroke, Nov. 2002, pp. 2711-2717.
Guojun Bu, “Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family”, Current Opinion in Lipidology, vol. 9, No. 2, Apr. 1998, pp. 149-155.
Gary A. Silverman et al., “The Serpins Are an Expanding Superfamily of Structurally Similar but Functionally Diverse Proteins”, The Journal of Biological Chemistry, vol. 276, No. 36, Issue of Sep. 7, 2001, pp. 33293-33296.
Jacek Otlewski et al., “Protein Inhibitors of Serine Proteinases”, Acta Biochimica Polonica, vol. 46, No. 3, 1999, pp. 531-565.
Robert Langer “Controlled release of macromolecules”, Chemtech, Feb. 1982, pp. 98-105.
Deborah A. Eppstein et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor”, Proc. Natl. Acad. Sci. USA, vol. 82, pp. 3688-3692, Jun. 1985.
Karl J. Hwang et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study”, Proc. Natl. Acad. Sci. USA vol. 77, No. 7, pp. 4030-4034, Jul. 1980.
Arti Shukla et al., “Metabolism of D-[3H]threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol, an inhibitor of glucosylceramide synthesis, an dhte synergistic action of an inhibitor of microsomal monooxygenase”, Journal of Lipid Research, vol. 32, 1991, pp. 713-722.
Francis Szoka et al., “Liposomes: Preparation and Characterization”, Liposomes: From Physical Structure to Therapeutic Applications, 1981, pp. 51-82.
Francis Szoka Jr. et al., “Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse phase evaporation”, Proc. Natl. Acad. Sci. USA, vol. 75, No. 9, pp. 4194-4198, Sep. 1978.
Sarah Netzel-Arnett et al., “Collagen Dissolution by Keratinocytes Requires Cell Surface Plasminogen Activation and Matrix Metalloproteinase Activity”, The Journal of Biological Chemistry, vol. 277, No. 47, Nov. 22, 2002, pp. 45154-45161.
Thiennu H. Vu et al., “MMP-9/Gelatinase B is a Key Regulator of Growth Plate Angiogenesis and Apoptosis of Hypertrophic Chondrocytes”, Cell., vol. 93, pp. 411-422, May 1, 1998.
Tomoko Betsuyaku et al., “Neutrophil Emigration in the Lungs, Peritoneum, and Skin Does Not Require Gelatinase B”, American Journal of Respiratory Cell and Molecular Biology, vol. 20, 1999, p. 1303-1309.
G. Pxaxinos et al., “The Mouse Brain in Stereotaxic Coordinates”, Second Edition, Academic Press Inc. San Diego CA (2001).
Olivier Nicole et al., “The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling”, Nature Medicine, vol. 7, No. 1,. Jan. 2001, pp. 59-64.
Guojun Bu et al., “Low density lipoprotein receptor-related protein/α2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator”, Proc. Natl. Acad. Sci., USA vol. 89, pp. 7427-7431, Aug. 1992.
Chia-Jen Siao et al., “Cell Type-Specific Roles for Tissue Plasminogen Activator Released by Neurons or Microglia after Excitotoxic Injury”, The Journal of Neuroscience, Apr. 15, 2003, 23(8):3234-3242.
Philippe Boucher et al., “LRP: Role in Vascular Wall Integrity and Protection from Atherosclerosis”, Science, vol. 300, Apr. 11, 2003, pp. 329-332.
Xi Jiang et al., “Storage and Release of Tissue Plasminogen Activator by Sympathetic Axons in Resistance Vessel Walls”, Microvascular Research 64, 438-447 (2002).
Vicenta Llorente-Cortės et al., “LDL Receptor-Related Protein Mediates Uptake of Aggregated LDL in Human Vascular Smooth Muscle Cells”, Arteriosclerosis, Thrombosis & Vascular Biology, Journal of the American Heart Association, 2000, 1572-1579.
Guojun Bu,
Lawrence Daniel A.
Strickland Dudley
Yepes Manuel S.
Marshall & Gerstein & Borun LLP
Mondesi Robert B.
The Regents of the University of Michigan
LandOfFree
Methods of reducing vascular permeability in tissue by... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of reducing vascular permeability in tissue by..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of reducing vascular permeability in tissue by... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2802740